Horse bone marrow mesenchymal stem cells express embryo stem cell markers and show the ability for tenogenic differentiation by in vitro exposure to BMP-12 by Violini, Stefania et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Cell Biology
Open Access Research article
Horse bone marrow mesenchymal stem cells express embryo stem 
cell markers and show the ability for tenogenic differentiation by in 
vitro exposure to BMP-12
Stefania Violini*, Paola Ramelli, Laura F Pisani, Chiara Gorni and 
Paola Mariani
Address: Livestock Genomics Unit, Parco Tecnologico Padano, CERSA, Via Einstein, Loc Cascina Codazza, 26900, Lodi, Italy
Email: Stefania Violini* - stefania.violini@tecnoparco.org; Paola Ramelli - paola.ramelli@tecnoparco.org; 
Laura F Pisani - laura.pisani@tecnoparco.org; Chiara Gorni - chiara.gorni@tecnoparco.org; Paola Mariani - paola.mariani@tecnoparco.org
* Corresponding author    
Abstract
Background: Mesenchymal stem cells (MSCs) have been recently investigated for their potential
use in regenerative medicine. MSCs, in particular, have great potential, as in various reports they
have shown pluripotency for differentiating into many different cell types. However, the ability of
MSCs to differentiate into tendon cells in vitro has not been fully investigated.
Results: In this study, we show that equine bone marrow mesenchymal stem cells (BM-MSCs),
defined by their expression of markers such as Oct4, Sox-2 and Nanog, have the capability to
differentiate in tenocytes. These differentiated cells express tendon-related markers including
tenomodulin and decorin. Moreover we show that the same BM-MSCs can differentiate in
osteocytes, as confirmed by alkaline phosphatase and von Kossa staining.
Conclusion: As MSCs represent an attractive tool for tendon tissue repair strategies, our data
suggest that bone marrow should be considered the preferred MSC source for therapeutic
approaches.
Background
Over the past few years in veterinary medicine there has
been an increased interest in understanding the biology of
mesenchymal stem cells (MSCs). This interest comes from
their potential clinical use especially in wound repair, tis-
sue engineering and application in therapeutics fields,
including regenerative surgery [1,2]. MSCs can be isolated
directly from bone marrow aspirates [3], adipose tissue
[4], umbilical cord [5] and various foetal tissues [6]. In the
appropriate cell culture conditions they have the capacity
to differentiate into several tissues [7], including bone [8],
cartilage [9], muscle [10], adipose tissue and produce
growth factors and cytokines promoting cell expansion
and differentiation [11]. MSCs are an interesting model
cell type to study differentiation mechanisms due to the
relative ease of establishing in vitro cultures and their good
proliferation [12]. Decades of experience have shown that
tendons and ligaments regenerate and repair slowly and
inefficiently  in vivo after injury. Strain induced tendon
injuries are a common consequence of athletic endeavour,
in both horses and humans, often compromising a return
to the previous level of activity. There are many similari-
ties between the weight bearing tendons of the horse and
human tendons, eg in matrix composition, and also in the
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nature of the injuries sustained. As tenocytes are highly
differentiated cells, they have a limited potential for repli-
cation. Moreover, tenocytes are embedded in an extensive
three-dimensional network of extracellular matrix com-
ponents consisting mostly of type I, type III and type V
proteoglycans, elastin and fibronectin [13-15].
The development of tendon tissue engineering for wound
repair will depend on the identification and characterisa-
tion of appropriate sources of cells, as well as the develop-
ment of new inert scaffolds for tissue regeneration [16].
The identification of an optimal cell source for tendon tis-
sue engineering applications will require a rigorous char-
acterisation of available sources for stem cells with regard
to plasticity, propagation and control of differentiation.
Under normal physiological conditions fully developed
tendon is a poorly vascularised tissue with a low density
of cells which exhibit low mitotic activities [17]. This
could explain why tendon healing is slow and in most
cases results in a mechanically inferior extracellular matrix
[18]. Tissue engineering approaches have been investi-
gated to improve tendon rupture healing by transplanta-
tion of in vitro cultured tenocytes, obtained from tendons,
seeded in matrices [19-21]. These cells are highly special-
ised mesenchyme-derived cells, responsible for the syn-
thesis and maintenance of a mechanically unique
connective tissue, able to resist high tensile forces [22].
Nevertheless, a critical drawback of cellular transplanta-
tion approaches using in vitro cultured tenocytes is the loss
of differentiated function that occurs during prolonged
monolayer culture [23]. MSCs, under appropriate stimu-
lation, represent an opportunity to produce in vitro cells of
the required type. Bone morphogenetic proteins (BMPs)
have been shown to induce differentiation of mesenchy-
mal stem cells into osteogenic lineage [24]. The bone
morphogenetic protein (BMP) family represents a sub-
group of molecules within the transforming growth factor
β (TGF-β) super family. BMPs were identified by their
ability to promote ectopic cartilage and bone formation
[25]. Among the BMPs isolated so far, BMP-2 and BMP-7
have been used to study tendon-bone healing in animal
models [26]. Most importantly, it has been shown that
gene transfer of BMP-12, a human homologue growth dif-
ferentiation factor 7 (GDF7), is required to induce teno-
cyte differentiation process in MSCs [27]. Therefore, using
BMP-12 to induce the development of MSCs into a suffi-
cient number of tenocytes for the repair of a tendon defect
was suggested [28]. Therefore adult stem cells, under spe-
cific stimulation represent a promising method to obtain
in vitro tenocytes for tendon healing.
In this study we describe the in vitro growth of equine
bone marrow MSCs. Cells were characterized using recog-
nized molecular markers for "stemness" namely: Nanog,
Oct4, Sox-2 and CD34. The undifferentiated cells were
morphologically characterized and the presence of PCR
products for the "stemness" markers assessed. The expres-
sion level of the latter was detected by QRT-PCR. Equine
MSCs were induced to differentiate either into osteoblasts
or into tenocytes by in vitro exposure to BMP-12. The
results are relevant to future tissue engineering applica-
tions of this approach to human and equine MSCs in clin-
ical practice.
Results
Cell morphology, growth characteristics and Oct4 
expression by immunocytochemistry
By day three after washing and removing the medium
containing non-adherent cells, equine BM-MSCs
appeared as isolated colonies of adherent elongated cells.
Following further passages the equine BM-MSCs cells pro-
liferated uniformly maintaining an homogeneous fibrob-
last-like morphology with a spindle shaped appearance
and growing outward in a "swirling fibroblast-like" pat-
tern. Nuclei were large and elliptical with the presence of
a few nucleoli (data not shown). Between 3rd and 10th pas-
sage the BM-MSCs had a doubling time of 1,8 days.
Immunocytochemical staining showed the expression of
Oct4 in most of BM-derived stem cells (Fig. 1).
Marker expression of BM-MS cells
The presence of Sox-2, Oct4 and Nanog amplicons in BM-
MSCs was assessed: the expression of these genes is
required for self-renewal and demonstrates multilineage
differentiation potential [29,30]. The cells did not express
the surface marker CD34, which is expressed in haemat-
opoietic but not in MSCs (Fig. 2).
The relative expression level of Sox-2, Oct4 and Nanog
was assessed by QRT-PCR. Data showed these "stemness"
markers to be expressed at comparable level with the con-
stitutive expression of the housekeeping GAPDH gene
(Fig. 3).
Tenogenesis of BM-MSCs
After tenogenesis induction cells were investigated for the
expression of tenocytes markers and found to express ten-
omodulin, which is a tendon-specific gene [31,32] and
decorin [33]. To rule out the possible unwanted differen-
tiation into reproduction tissues, the expression of P19
lipocalin was checked (Fig. 4). Differentiated cells did not
show P19 expression. This gene is not expressed in teno-
cytes and is expressed by horse uterine and endometrial
tissues [34]. Compared to the untreated BM-MSCs, the
differentiated cells showed a significant difference in mor-
phology some being fibroblast-like and others having a
more elongated tenocyte-like phenotype (Fig. 5).BMC Cell Biology 2009, 10:29 http://www.biomedcentral.com/1471-2121/10/29
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Osteogenic potential of BM-MSCs
Osteogenic differentiation was induced in the BM-MSCs
by a medium containing β-glycerol phosphate, ascorbic
acid and dexamethasone. The BM-MSCs formed calcium
deposits identified by von Kossa staining (Fig. 6), suggest-
ing the osteogenic potential of our MSCs culture. Moreo-
ver, cells stained positively for alkaline phosphatase,
which is an indicator of osteogenic differentiation. Fol-
lowing osteogenic induction, the cells changed their mor-
phology and showed more cubical and star-shaped
morphology with spikely extensions and increased in size.
Neither positive staining for alkaline phosphatase or min-
eralized matrix was observed in the cells cultured in regu-
lar growth medium.
Discussion
Bone marrow mesenchymal stem cells (BM-MSCs) have
been recently investigated as important source of undiffer-
entiated cells in the field of regenerative medicine. As they
can potentially differentiate into chondrocytes, adi-
pocytes, osteocytes, myocardial and neural cells, they have
become promising candidates as starting cells in tissue
engineering studies aimed at improving wound healing
and tendon tissue repair [35,36]. The technique of equine
MSC isolation from bone marrow, ex vivo culture and
expansion, has been previously reported [37]. Recently,
Vidal described adipose-derive stem cell (ADSC) charac-
teristics compared to BM-derived stem cells [38], men-
tioning their clinical relevance for tissue engineering
applications in equine veterinary medicine, making adi-
pose tissue a possible alternative source to BM.
BM-derived MSCs express stem cell marker protein Oct4 Figure 1
BM-derived MSCs express stem cell marker protein Oct4. Cells (5th passage) were fixed and incubated with antibod-
ies directed against Oct4. Immunoreactivity was detected with avidin, biotinylated horseradish peroxydase and 3,3'-Diami-
nobenzidine (DAB) (1B). 1A: negative control, incubated only with secondary antibody. Magnification 20×.
                   
A                          B 
    
Gene expression analysis of BM-MSCs Figure 2
Gene expression analysis of BM-MSCs. The products 
from RT-PCR analysis of GAPDH (lane 1), Oct4 (lane 2), 
CD34 (lane 3), SOX-2 (lane 4) and Nanog (lane 5) mRNA 
expression at day 14 (passage 5) in BM-MSCs, showing the 
expression of mesenchymal stem cell-related markers and 
lack of expression of CD34.
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Though ADSCs have been reported to display similar
characteristics to BM-MSCs in humans in terms of gene
expression profiles and phenotypes [39,40], their poten-
tial for both chondrogenic differentiation in 3D culture
and proteoglycan synthesis and thus their quality in tissue
engineering is controversial [40,41]. Winter and co-work-
ers [40] found 90% reduced chondrogenic potential of
ADSCs in micromass cultures compared to BM-MSCs and
these observations were confirmed by Sakaguchi and co-
workers [42], who analyzed various stem cell sources in
chondrogenesis studies. Scientific literature has already
shown that the methods to isolate BM-MSCs are faster
than ADSCs and the yield in terms of purity is higher as in
the latter case cells might be contaminated by mixed pop-
ulation of fibroblasts and adipocytes [43]. Moreover,
Richardson and co-workers [43] reported MSCs isolation
from fat is riskier than from bone marrow as there is more
donor-site morbidity because of the surgery.
In general, tendon lesions in horses have been treated
with BM-MSCs [35]. These cells have been largely used
since they have been shown to be successful in repairing
more specifically tendons and ligaments [36].
Adipose stem cell plasticity seems to be limited though
compared to BM, as differentiation capabilities in tendon-
like cells is still to be proven [44].
The focus of this study was to evaluate growth and differ-
entiation of equine BM-MSCs. Adherent cells from bone
marrow were found to actively proliferate in vitro and to
maintain their morphological and growth characteristics
for over 10 passages. Moreover, our results show that
adherent equine BM-MSCs could proliferate rapidly in
DMEM with FBS and EGF added with a doubling time of
1.8 day. This finding is comparable to previous studies
that found an average cells doubling time of 1.4 days, with
no significant difference in the doubling rate between
foals and young horses BM-MSCs [38]. In our study cells
grown in standard media showed an elongated fibroblast-
like morphology, large cell size and capabilities of contin-
uously dividing as has been observed in bone marrow
stroma and tissue-specific MSC cells from other species
[45,46]. RT-PCR analysis showed that Oct4, Nanog and
Sox-2 genes were expressed by the stem cells. The follow-
ing QRT-PCR showed these "stemness" markers were
expressed at comparable level with the constitutive gene
GAPDH. This data confirms that MSCs from bone marrow
of adult animals also expresses embryonic stem cell mark-
ers.
QRT-PCR of BM-MSCs for the Nanog, Oct4, Sox2 and GAPDH genes Figure 3
QRT-PCR of BM-MSCs for the Nanog, Oct4, Sox2 and GAPDH genes. Plot of QRT-PCR of Nanog (violet), Oct4 
(green), Sox2 (blue) and GAPDH (red) on cDNA from BM-MSC cells. Cycle number is shown on the X-axis and emission 
intensity of a fluorescent reporter (Rn) is shown on the Y-axis. Fixed threshold is indicated as horizontal line.BMC Cell Biology 2009, 10:29 http://www.biomedcentral.com/1471-2121/10/29
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Immunocytochemistry experiments confirmed that BM-
MSCs expressed the embryo stem cell marker Oct4. These
cells did not express the haematopoietic lineage marker
CD34, thus confirming their characterisation as mesen-
chymal stem cells [46]. Interestingly, so far only embry-
onic stem cells had been found to express Oct4 and
Nanog [47]. Recently, two papers reported the expression
of Oct4 in equine umbilical cord cells [44,48]. In our
study we show that also bone marrow-derived mesenchy-
mal stem cells do express both Oct4 and Nanog. Literature
data have considered embryo and adult stem cell markers
as part of two different groups of markers. Our discovery
that horse bone marrow MSCs express Oct4 and Nanog,
together with a documented expression of SSEA-1 in
murine MSCs by Anjos-Afonso [49], might indicate that
the distinction between embryo and adult markers is not
so strict. Having assessed in the present study that embryo
stem cell markers are also expressed by adult stem cells,
further investigations in the field are needed to identify
which still unknown markers are unique and peculiar for
embryo stem cells and to characterize embryological pat-
terns in terms of differentiation capabilities. It should be
noted that in our study the expression of equine cell mark-
ers was assessed by a PCR based panel of specifically
designed oligonucleotide primers, instead of using anti-
gen/antibodies based flow cytometry. This panel was used
not only to assess the stemness of bone marrow-derived
cells, but also to investigate their differentiation in teno-
cytes. This DNA marker-based panel represents a powerful
tool in equine stem cells research, as many positive stem-
Gene expression analysis of BM-MSC derived tenocytes Figure 4
Gene expression analysis of BM-MSC derived teno-
cytes. Products from RT-PCR analysis of tenomodulin (lane 
1), P19 lipocalin (lane 3), GAPDH (lane 3) and decorin (lane 
4) mRNA expression following 14 days stimulation of BM-
MSC cells with BMP-12, resulting in differentiation into teno-
cytes.
 
       1       2         3         4 
Morphology of equine BM-MSC-derived tenocytes cultured in monolayer at day 20th Figure 5
Morphology of equine BM-MSC-derived tenocytes cultured in monolayer at day 20th. The cells at 5th passage in 
growth medium added with BMP-12 under phase contrast microscopy exhibited heterogeneous morphology with most cells 
fibroblast-like (A) and other elongated cells (B). Magnification 10×.
A                B 
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cell marker antibodies, so far described in other species,
show little or no cross-reactivity and thus cannot be used
in the horse [45,46].
In this paper we show that horse BM-MSCs can be
induced to differentiate in tenocytes. Following exposure
to BMP-12 the BM-MSCs expressed two tendon-related
markers, tenomodulin and decorin [31-33]. To rule out
the possibility that BMP-12 had induced differentiation
into other cell types, rather than tenocytes, P19 lipocalin
expression was assayed. In the BM-MSCs no expression of
this gene, which is known to be expressed in reproductive
system tissues like endometrium and uterus [34] was
assessed. The BM-MSCs also maintained their capability
to differentiate into osteoblast lineage, which was con-
firmed by two different staining techniques to detect the
presence of calcium deposits and positivity for alkaline
phosphatase. In literature many reports have shown that
MSCs have multilineage differentiation capabilities [7-
10]. However, up to now there has been no report of ten-
ocytes induction. Although the possibility of using trans-
planted mesenchymal stem cells for tissue repair has been
suggested in rabbits [50], little it is known about capabil-
ity of mesenchymal stem cells to differentiate into tissue-
BM-MSCs osteogenic induction: alkaline phosphatase (AP) and von Kossa staining Figure 6
BM-MSCs osteogenic induction: alkaline phosphatase (AP) and von Kossa staining. After osteogenic induction cells 
showed a completely different morphology compared to untreated MSCs. (A, C): untreated control cells showing no staining 
for AP and von Kossa respectively (Magnification 10×). (B, D): AP and von Kossa positive staining in bone marrow-derived 
osteogenic cells. Magnification 20×.
 A                               B 
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specific cell types in vivo. However, a combination of
mechanical stimuli and proximity to tenocytes and ten-
don matrix are believed to be important as stimuli for dif-
ferentiation into tendon cells, as shown by direct
implantation of cells into the tendon. The transplantation
of mesenchymal stem cells into injured tendons has been
shown to promote tendon healing not only in laboratory
animal models [50] but also in horses [51,52].
PLGA (poly(lactic-co-glycolic acid) fibres have been used
as scaffolds in therapeutic approaches to tendon repair,
owing to their biodegradability and biocompatibility
[53]. However, 3D scaffolds have not shown any results in
the case of tendon repair in horses. So far, many
approaches have been investigated for improvements in
tendon injury repair, but most are not completely under-
stood and much further effort is necessary to develop the
technology into a highly efficient treatment. The promise
of functional tissue engineering to replace damaged
organs or tissues has boosted research interest. At present,
however, it is important to balance the understanding of
our current limitations with a desire to progress the tech-
nology. The possibility to use MSCs that have been pre-
differentiated into tendon cells for transplantation may
represent a significant improvement over the use of undif-
ferentiated cells.
For instance, there are some evidences of tumor induction
by undifferentiated cells; more investigations in this mat-
ter, though, are needed [54].
Conclusion
In summary, our study has confirmed, at molecular level
through gene specific DNA markers and their expression
patterns, that BM-MSCs possess the capability of differen-
tiating into tenocytes. These data will be the basis of future
efforts to standardize the isolation, expansion and trans-
plantation of equine differentiated and undifferentiated
stem cells in clinical practice.
Methods
Isolation of BM cells
Bone marrow (BM) samples were obtained aseptically
from sternal aspirates of an 8-year-old Dutch Warmblood
mare during surgery for hock arthroscopy under general
anesthesia with the owner consensus at the Large Animal
Hospital of the Faculty of Veterinary Medicine in Lodi.
The harvest site was clean shaved, clipped and aseptically
prepared.
The intersternebral spaces were easily identified by diag-
nostic ultrasonography and bone marrow needles (11
gauge, 10 cm) were used to aspirate marrow in two 20 ml
syringes containing 30,000 units of sodium heparin each
(Teofarma, Pavia, Italy). Immediately after collection,
samples were stored on ice.
Preparation of MSC was achieved as follows. BM (30 ml)
was layered over Hystopaque™ 1.077 (Sigma Aldrich, St.
Louis, MO) and centrifuged for 20 min at 400 g and 4°C.
The MSC-enriched cell population above the Hysto-
paque™ layer was aspirated and washed in calcium and
magnesium-free Dulbecco's Phosphate Buffered Solution
(PBS) by further centrifugation at 260 g for 5 minutes at
4°C. The cell pellets were resuspended in 10 ml Dulbecco
Modified Earle's Medium (DMEM) supplemented with
10% fetal calf serum (FCS), penicillin (100 U/ml) and
streptomycin (P/S) (100 μg/ml), non-essential amino
acids (NEAA 1%), and seeded in 24-well plates (TPP, Tras-
adingen, Switzerland). All reagents were purchased from
Euroclone (Milan, Italy).
Cells were checked for adhesion 3–4 days after plating
and the medium was replaced with fresh medium con-
taining Epidermal Growth factor (EGF) 50 ng/ml as spe-
cific growth factor (R&D System, Minneapolis, MN). After
2 weeks, when the cells were actively proliferating, they
were sub-cultured every 3–4 days, counted and seeded in
T25 flasks (4 × 105 cells/flask) or 24-well plates (2 × 105
cells/ml) and incubated at 37°C, 5% CO2. Photographs
under AE30 Motic phase-contrast microscope were taken
at passage 3.
Proliferation study
To determine BM-MSCs doubling time, cells were plated
at a density of 7,5 × 103 nucleated cells/well in a 6-well
plate (Corning Inc, Corning, NY) and incubated in the
growth medium described above. Cells were harvested
daily sequentially from replicate cultures over seven con-
secutive days and cell number determined using a Burker
chamber. Experiments were performed in triplicate. The
mean number of cells was calculated and plotted on a
common log scale against culture time to generate a
growth curve. The mean doubling time was obtained by
the formula [55]: PD = (lgNt-lgN0)/lg2 where N0 is the ini-
tial cell number; Nt is the cell harvest number at time t.
Doubling times between day 1 and day 7 in culture were
calculated.
Immunocytochemistry
Cultured BM-derived stem cells were formalin fixed for 10
min, washed in PBS and permeabilized with 0.1% (v/v)
Triton X-100 in PBS for 20 min. Cells were incubated with
1:50 specific goat polyclonal antibody raised against Oct4
(Santa Cruz Biotechnology, Germany) for 2 h at 37°C,
followed by incubation for 2 h at room temperature with
secondary biotin-conjugated donkey anti-goat IgG anti-
body (1:200) (Santa Cruz Biotechnology, Germany). Neg-
ative controls were incubated only with secondaryBMC Cell Biology 2009, 10:29 http://www.biomedcentral.com/1471-2121/10/29
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antibody under the above condition. Excess secondary
antibody was removed by repeated washing with PBS.
Avidin, biotinylated horseradish peroxydase and 3,3'-
Diaminobenzidine (DAB) were applied according to the
manufacturer's instructions using Vectastain ABC kit
(DBA Italia s.r.l., Italy). Images were obtained with a
phase contrast microscope under a 20× magnification.
"Stemness" Marker Analysis
RT-PCR reaction and conditions
Total RNA was isolated from BM-MSCs at 5th passage
using the RNeasy kit (Qiagen, Milan, Italy). Total RNA
was dissolved in 30 μl of RNase-free water and was kept at
-80°C until analysis. The RNA concentration was deter-
mined using a NanoDrop ND-1000 spectrophotometer
(NanoDrop, Wilmington, DE). Total RNA (0.5 μg) was
converted to cDNA with RevertAid H Minus M-MLV RT
reverse transcriptase (Fermentas Int. Inc, Ontario). The
obtained cDNA was amplified in 1× PCR buffer, with 0.5
μM sense and antisense primers, and 5 U Taq Gold
polymerase (Applied Biosystem, Foster City, CA) using an
Eppendorf Mastercycler Gradient (Eppendorf AG, Ger-
many).
Gene-specific amplicons for the Nanog, Oct4, Sox2 and
CD34 genes were obtained using primer pairs designed
based on equine gene specific sequences where available,
otherwise primers were designed using gene specific
sequences from other species that are present in public
databases (Table 1; primer sequences for the characteriza-
tion protocol of equine stem cells are covered by patent
applications owned by Fondazione Parco Tecnologico
Padano).
The conditions for PCR amplification were as follows: 10
minutes at 95°C, followed by 35 cycles of 45 seconds at
95°C, 30 seconds at 58°C, 30 seconds at 72°C, followed
by a final extension step of 5 minutes at 72°C. PCR prod-
ucts were resolved by electrophoresis on 2% agarose gels,
visualized by ethidium bromide staining and photo-
graphed under ultraviolet light trans-illuminator (Bio-
Rad, Hercules, CA).
Quantitative RT-PCR reaction and conditions
BM-MSCs cDNA was used as the template for QRT-PCR of
Nanog, Oct4 and Sox2 genes. Analysis of GAPDH gene
was added as reference for housekeeping gene expression
level.
All reactions were carried out in a total volume of 10 μl,
containing 0.5 μM of each primer, 5 μl of Sybrgreen mas-
ter mix 2× (Applied Biosystems) and 5–10 ng cDNA. Each
PCR reaction was carried out in triplicate and amplifica-
tions were performed using an ABI Gene Amplification
7900 Sequence Detection System (Applied Biosystems,
Foster City, CA). A single optimized thermal protocol of
95°C for 10 minutes, 40 cycles of 95°C for 30 seconds,
61°C for 1 minute and a final extension at 72°C for 5
minutes was used for all primer pairs. Dissociation curve
analysis was run to ensure the absence of non-specific
product.
Table 1: Polymerase chain reaction (PCR) primer sequences
GAPDH F: CAACGAATTTGGCTACAGCA
R: CTGTGAGGAGGGGAGATTCA
CD34 F: ATTACACGGAAAACGGTGGA
R: AATTCGGTATCAGCCACCAC
Oct4 F: TCCCAGGACATCAAAGCTGCAGA
R: GTCAAACTTACGTACCCTCTCGGGTCT
NANOG F: TACCTCAGCCTCCAGCAGAT
R: CATTGGTTTTTCTGCCACCT
SOX-2 F: TGGTTACCTCTTCCTCCCACT
R: GGGCAGTGTGCCGTTAAT
TENOMODULIN F: GATCTTCACTTCCCTACCAACG
R: CTCATCCAGCATGGGGTC
DECORIN F: GAATGAGATCACCAAGCTGC
R: TGAGATGCGAATGTATGAGAGA
LIPOCALIN F: TTCTTCATCCACAAGATCCAG
R: AGTTGGGACACACATACCTCTTBMC Cell Biology 2009, 10:29 http://www.biomedcentral.com/1471-2121/10/29
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Data Analysis
The ΔΔCT method [56] was used to evaluate the relative
expression levels among Nanog, Oct4 and Sox2 genes,
using GAPDH as housekeeping gene.
In Vitro Differentiation of BM-MSCs into tenocytes
At the 5th passage when BM-MSCs were 70% confluent,
cells were trypsinized, counted and plated at a density of
6 × 105 onto a T25 culture flask. To induce tenocyte differ-
entiation, cell cultures were maintained for 14–21 days in
growth medium supplemented with BMP-12 50 ng/ml
(Tebu-Bio, Milan, Italy). The medium was changed every
other day.
Osteogenic differentiation
BM-MSCs were plated at density of 1 × 104 cells/well and
cultured in a 6-well-plate. Induction medium consisted of
DMEM-HG, 10% FCS, 1× P/S, 0.1 μmol/l dexamethasone,
0.025 mmol/l ascorbic acid-2-phosphate and 10 mmol/l
β-glycerophosphate. All reagents were purchased from
Sigma. Cells maintained in regular growth medium were
used as negative control. After 2 weeks of induction, the
cells were stained using the von Kossa procedure [57] to
detect the presence of calcium deposition in osteocyte pre-
cursors. The positive and negative controls were also
stained for alkaline phosphatase (Chemicon, Temecula,
CA) according to the procedures described by the manu-
facturer. All the experiments were performed in triplicate.
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